Investigating the role of liquid-liquid phase separation in the interaction between Mycobacterium tuberculosis and macrophages
Project Number5DP2AI154429-04
Former Number5DP2AI154429-03
Contact PI/Project LeaderBELL, SAMANTHA LYNN
Awardee OrganizationRUTGERS BIOMEDICAL AND HEALTH SCIENCES
Description
Abstract Text
PROJECT SUMMARY
There is a fundamental gap in our understanding of the complex processes that govern the interactions between
Mtb and macrophages. The overall objective of this application is to investigate how the novel biophysical
phenomenon of phase separation impacts biological processes, specifically in the context of Mtb infection. A
detailed knowledge of the molecules that recognize and respond to pathogens is required to reveal how cells
fight infection; therefore, there is a critical need to understand how phase separation may influence or control
innate immune responses. Mycobacterium tuberculosis (Mtb) is an incredibly successful and deadly human
pathogen that infects one-quarter of the world's population. While interaction of Mtb bacilli and macrophages
activates numerous innate immune pathways, we have a limited understanding of how these complex networks
of host sensing molecules are regulated to work cooperatively. Furthermore, only a small subset of the many
secreted effectors used by M. tuberculosis have well-characterized functions. Recent studies have illuminated
the biological and cellular importance of liquid-liquid phase separation, a process by which proteins condense
into discrete droplets to alter their localization and function in a cell. Several proteins involved in the host
response to M. tuberculosis infection, like cGAS, TBK1, p62, and LC3, have been found to phase separate in
vitro, but how in vivo phase separation impacts host responses to infection is unknown. Preliminary studies have
found that these and other innate immune proteins form circular puncta in M. tuberculosis-infected cells that
resemble phase separated droplets. The central hypothesis of this proposal is that upon infection, pathogen-
sensing and post-translational modifications induce phase separation of host proteins and that Mtb modulates
these condensation events with its own phase-separating PE/PPE proteins. Here, a combination of novel
optogenetics tools, live cell fluorescent imaging, and host and bacterial genetics will be employed to probe the
biological consequences of phase separation of host proteins (Aim 1) and Mtb proteins (Aim 2). In addition,
directed and unbiased genetics approaches will be used to probe how post-translational modifications, and
especially ubiquitination in particular, contributes to phase separation during Mtb infection (Aim 3). This approach
is innovative in that it uses novel tools to specifically and precisely modulate phase separation in order to link
this biophysical process with meaningful cellular phenotypes. The proposed research is significant because it
will greatly expand our understanding of how macrophages destroy Mtb and advance efforts to combat Mtb
infection via enhancing host responses.
Public Health Relevance Statement
PROJECT NARRATIVE
The proposed research is relevant to human health because Mycobacterium tuberculosis (Mtb) is the number
one infectious disease killer in the world. The ability of innate immune cells to kill or control Mtb infection is critical
for disease outcomes. Therefore, I aim to understand how this process is regulated in hopes of one day
developing therapeutics designed to enhance macrophages' antibacterial responses and control infection in
human patients. The proposed research is relevant to the part of NIH's mission that pertains to making
fundamental discoveries that will help prevent and treat disease.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AffectAntibacterial ResponseAntibiotic ResistanceAutomobile DrivingAutophagocytosisBacillusBiochemicalBiochemistryBiologicalBiological ProcessBiophysical ProcessBiophysicsCell NucleusCell membraneCellsCellular biologyCommunicable DiseasesComplexCytoplasmDataDefense MechanismsDevelopmentDiseaseDisease OutcomeEventGalactose Binding LectinHealthHumanImmuneImmune responseImmune systemIn VitroIndividualInfectionInfection ControlInnate Immune ResponseKnowledgeLinkLiquid substanceMacrophageMembraneMicrobiologyMissionModificationMolecularMolecular BiologyMycobacterium tuberculosisNatural ImmunityOrganellesPathogenesisPatient-Focused OutcomesPatientsPersonsPhasePhenotypePhosphorylationPhysical condensationPolyubiquitinationPopulationPost-Translational Protein ProcessingProcessProteinsProteomicsReactionRecording of previous eventsRegulationReportingResearchRoleSignal TransductionStimulator of Interferon GenesStructureTBK1 geneTestingTherapeuticTrainingTuberculosisUbiquitinationUnited States National Institutes of HealthWorkbacterial geneticscombatdesignexperimental studyfightingfluorescence imaginggenetic approachhuman pathogenin vivoinnate immune pathwaysinnovationinterdisciplinary approachlive cell imagingnovelnovel therapeuticsoptogeneticspathogenpreventresponsetool
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
090299830
UEI
YVVTQD8CJC79
Project Start Date
10-August-2021
Project End Date
31-July-2026
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$466,072
Direct Costs
$300,000
Indirect Costs
$166,072
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$466,072
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5DP2AI154429-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5DP2AI154429-04
Patents
No Patents information available for 5DP2AI154429-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5DP2AI154429-04
Clinical Studies
No Clinical Studies information available for 5DP2AI154429-04
News and More
Related News Releases
No news release information available for 5DP2AI154429-04
History
No Historical information available for 5DP2AI154429-04
Similar Projects
No Similar Projects information available for 5DP2AI154429-04